David Seftel
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$10.6MFederal grants as PI17 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
17 awards · $10.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 29, 2025 | NIH | SBIR Phase II Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance | $961K | Enable Biosciences Inc. |
| Aug 1, 2024 | NIH | SBIR Phase II Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance | $968K | Enable Biosciences Inc. |
| May 22, 2023 | NIH | SBIR Phase II Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance | $990K | Enable Biosciences Inc. |
| May 5, 2021 | NIH | SBIR Phase II Multiplex food allergy diagnostic based on IgE immunologic markers | $645K | Enable Biosciences Inc. |
| Sep 1, 2020 | NIH | SBIR Phase II Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk | $741K | Enable Biosciences Inc. |
| Apr 6, 2020 | NIH | SBIR Phase II Multiplex food allergy diagnostic based on IgE immunologic markers | $846K | Enable Biosciences Inc. |
| Sep 18, 2019 | NIH | SBIR Phase II Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk | $747K | Enable Biosciences Inc. |
| Mar 27, 2019 | NIH | SBIR Phase II An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes | $750K | Enable Biosciences Inc. |
| Mar 11, 2019 | NIH | SBIR Phase I Early and accurate differential diagnosis of Lyme and other tick-borne diseases by agglutination-PCR | $225K | Enable Biosciences Inc. |
| Aug 8, 2018 | NIH | SBIR Phase I Multiplex food allergy diagnostic based on IgE immunologic markers | $224K | Enable Biosciences Inc. |
| Aug 8, 2018 | NIH | SBIR Phase I Multiplex food allergy diagnostic based on IgE immunologic markers | $224K | Enable Biosciences Inc. |
| Apr 20, 2018 | NIH | SBIR Phase II An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes | $750K | Enable Biosciences Inc. |
| Mar 8, 2018 | NSF | SBIR Phase II SBIR Phase II: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR | $900K | Enable Biosciences Inc. |
| Mar 1, 2018 | NSF | SBIR Phase II SBIR Phase II: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR | $900K | Enable Biosciences Inc. |
| Jul 18, 2016 | NIH | SBIR Phase I Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring | $224K | Enable Biosciences Inc. |
| Jul 1, 2016 | NSF | SBIR Phase I SBIR Phase I: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR | $270K | Enable Biosciences Inc. |
| Jun 22, 2016 | NSF | SBIR Phase I SBIR Phase I: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR | $270K | Enable Biosciences Inc. |
Peer ranks
Federal funding#66
Awards as PI#45
Patents#505
Companies
- Enable Biosciences Inc.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.